A non-canonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer I
RNA-seq (gene expression) · human · 16 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 16 samples: 4 × T47D Cntr DMSO vs 4 × T47D Cntr ABE vs 4 × T47D KO DMSO vs 4 × T47D KO ABEGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE330516_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1464538 and SRA study SRP699268. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 16 samples.
How we read this: 4 replicated groups read from 16 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9728019 T47D Cntr DMSO_1 T47D Cntr DMSO
- GSM9728020 T47D Cntr DMSO_2 T47D Cntr DMSO
- GSM9728021 T47D Cntr DMSO_3 T47D Cntr DMSO
- GSM9728022 T47D Cntr DMSO_4 T47D Cntr DMSO
- GSM9728023 T47D Cntr ABE_1 T47D Cntr ABE
- GSM9728024 T47D Cntr ABE_2 T47D Cntr ABE
- GSM9728025 T47D Cntr ABE_3 T47D Cntr ABE
- GSM9728026 T47D Cntr ABE_4 T47D Cntr ABE
- GSM9728027 T47D KO DMSO_1 T47D KO DMSO
- GSM9728028 T47D KO DMSO_2 T47D KO DMSO
- GSM9728029 T47D KO DMSO_3 T47D KO DMSO
- GSM9728030 T47D KO DMSO_4 T47D KO DMSO
- GSM9728031 T47D KO ABE_1 T47D KO ABE
- GSM9728032 T47D KO ABE_2 T47D KO ABE
- GSM9728033 T47D KO ABE_3 T47D KO ABE
- GSM9728034 T47D KO ABE_4 T47D KO ABE
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares resistance
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE330518 A non-canonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer II 12 samples shares cdk4, fah, non-canonical, degradation, resistance, inhibitor, tyrosine, enzyme
- GSE308451 CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers 90 samples shares cdk4, resistance, inhibitor
- GSE296805 An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer 50 samples shares cdk4, resistance, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.